What does Kura Oncology, Inc. do?
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes…
What is Kura Oncology, Inc.'s P/E and P/B ratio?
Kura Oncology, Inc. has a P/E ratio of -2.9 and a P/B ratio of 18.11.
What is Kura Oncology, Inc.'s debt-to-equity ratio?
Kura Oncology, Inc. has a debt-to-equity ratio of 0.51.
How much does Kura Oncology, Inc. owe compared with what it owns?
Kura Oncology, Inc. owes $0.92 for every $1 it owns (balance sheet Jun 2026), which is high.
What is Kura Oncology, Inc.'s Positivity rank?
Kura Oncology, Inc. is ranked #6,051 of 6,774 companies globally and #3,423 of 4,000 in United States on PositoAI, with a Positivity Score of 10,946.
Does Kura Oncology, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Kura Oncology, Inc..
Where can I read the latest news about Kura Oncology, Inc.?
Recent headlines about Kura Oncology, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Kura Oncology, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Kura Oncology, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.